Summary & Overview
CPT 0549U: Bladder CARE™ Urine DNA Methylation Assay
CPT code 0549U identifies a Proprietary Laboratory Analyses (PLA) test — Bladder CARE™ from Pangea Laboratory LLC — that measures DNA methylation of three genes in urine to produce a probability index for bladder cancer and upper tract urothelial carcinoma (UTUC). As a PLA code, 0549U maps to a single manufacturer-specific laboratory test and signals unique clinical utility in noninvasive urothelial cancer detection and surveillance. Nationally, molecular urine assays are increasingly relevant for risk stratification, surveillance protocols, and reducing invasive procedures when appropriate.
Key payers covered in this profile include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical intent and service setting, an explanation of the code’s PLA status, and what the code represents for billing and laboratory reporting. The publication outlines typical benchmarks and policy considerations relevant to payer coverage and claims processing, summarizes clinical context for interpretation of test results, and highlights common administrative elements associated with laboratory molecular diagnostics. Data not available in the input will be identified where applicable.
Billing Code Overview
CPT code 0549U is a Proprietary Laboratory Analyses (PLA) code assigned specifically to the Bladder CARE™ test from Pangea Laboratory LLC. The test analyzes DNA methylation levels of three genes (TRNA–Cys, SIM2, and NKX1–1) using a quantitative methylated real–time polymerase chain reaction (PCR) method to generate a probability index for the likelihood of bladder cancer or upper tract urothelial carcinoma (UTUC).
Service type: Molecular diagnostic urine-based assay
Typical site of service: Clinical laboratory testing performed on urine specimens; specimen collection may occur in outpatient clinics, urology practices, or patient collection at home with subsequent laboratory processing.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with a history of painless gross hematuria and prior tobacco use presents to a urology clinic for evaluation. After initial cystoscopy and urine cytology are performed, the clinician orders the Bladder CARE™ urine-based methylation assay (0549U) to noninvasively assess the probability of urothelial carcinoma, including bladder cancer or upper tract urothelial carcinoma (UTUC). A urine specimen is collected in clinic and sent to Pangea Laboratory LLC. The laboratory performs quantitative methylated real-time PCR targeting methylation of TRNA–Cys, SIM2, and NKX1–1, and reports a probability index indicating the likelihood of urothelial cancer. Results are used by the urologist in conjunction with imaging, cystoscopy findings, and cytology to guide need for further diagnostic procedures (for example, repeat cystoscopy, ureteroscopy, or cross-sectional imaging) and surveillance planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default (no modifier) | Use when no special circumstances apply to the billed test. |
22 | Increased procedural services | Use when unusual effort or additional work beyond the usual laboratory procedure is documented and meets payer criteria.
52 | Reduced services | Use when the laboratory service was partially reduced or not completed as described in CPT.
53 | Discontinued procedure | Use when specimen collection or testing was started but discontinued for reasons documented in the medical record.
59 | Distinct procedural service | Use when another distinct and separate service is provided and properly documented (apply cautiously for labs per payer rules).
TC | Technical component | Use if billing only the technical component of a test (rare for PLA codes; check payer rules).
26 | Professional component | Use if billing only the professional component (result interpretation) separate from the performing lab.
90 | Reference (outside) laboratory | Use when the test is performed by an outside laboratory and billing needs to indicate reference lab processing.
91 | Repeat clinical diagnostic laboratory test | Use when reporting repeat testing on the same day to confirm prior results.
99 | Multiple modifiers (placeholder for other payer-specific uses) | Use per payer guidance when multiple modifiers are required and CMS does not specify an exact code.
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207L00000X | Urology | Urologists commonly order urine-based bladder cancer assays and integrate results into diagnostic algorithms. |
208600000X | Pathology | Pathologists and molecular diagnostic laboratories interpret and oversee molecular testing workflows.
363L00000X | Clinical Laboratory | Clinical laboratorians and clinical chemistry specialists perform and report the assay in a certified lab.
207RH0000X | Hematology/Oncology | Medical oncologists may use results for risk stratification in patients with urothelial carcinoma.
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
R31.9 | Hematuria, unspecified | Hematuria is a common presenting symptom prompting urine testing, cytology, cystoscopy, and molecular assays such as Bladder CARE™. |
C67.9 | Malignant neoplasm of bladder, unspecified | Known or suspected bladder cancer is the primary diagnostic indication for a urinary methylation assay to assess likelihood of urothelial carcinoma.
C65.9 | Malignant neoplasm of renal pelvis, unspecified | Upper tract urothelial carcinoma (UTUC) can be detected via urine-based assays and is part of the clinical spectrum evaluated by this test.
N13.7 | Hydronephrosis with renal and ureteral calculous obstruction | Imaging and molecular testing may be correlated when obstructive symptoms coexist with hematuria to differentiate malignant versus benign causes.
Z85.51 | Personal history of malignant neoplasm of bladder | Surveillance testing in patients with prior bladder cancer may include urine-based molecular assays to detect recurrence.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
81001 | Urinalysis, non-automated, with microscopy | Initial urine testing often performed prior to or alongside collection for the Bladder CARE™ assay to evaluate hematuria and urinary abnormalities. |
88112 | Cytopathology, body fluid, non-gynecologic (eg, urine), except using ThinPrep or other specified methods | Urine cytology is commonly ordered concurrently to evaluate for malignant urothelial cells and complements methylation assay results.
52000 | Cystourethroscopy, diagnostic, with or without collection of specimen by brushing or washing | Diagnostic cystoscopy is a standard procedural correlate when bladder cancer is suspected and often precedes molecular urine testing.
74250 | Urography, radiologic, with contrast (intravenous) | Cross-sectional imaging such as CT urogram or IVP for assessment of upper tract pathology may be ordered in the diagnostic pathway.
81275 | BRAF (v-raf murine sarcoma viral oncogene homolog B1) gene analysis (example of molecular test) | Representative molecular/genetic testing CPT code for laboratory workflow context; molecular assays may be part of comprehensive evaluation though not specific to Bladder CARE™.